Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lambda carrageenan is a natural sulfated polysaccharide derived from red seaweed (Rhodophyceae). Unlike kappa and iota carrageenans, lambda carrageenan contains three sulfate groups per disaccharide unit and lacks 3,6-anhydrogalactose, which prevents it from forming a rigid gel and allows it to remain as a highly viscous, soluble random coil in aqueous solutions. It acts as a broad-spectrum, virus-agnostic entry inhibitor. Its negatively charged ester sulfate groups bind via electrostatic interactions to positively charged viral surface proteins (such as the L1 capsid protein of HPV, gp120 of HIV-1, hemagglutinin of influenza, and the spike protein of SARS-CoV-2), physically blocking viral attachment and entry into host cells. It has been clinically evaluated in vaginal gel formulations (such as PC-503 and Divine 9) for the prevention of sexually transmitted infections, demonstrating significant protective efficacy against human papillomavirus (HPV) in Phase II trials, and is also being investigated for the prevention of respiratory viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lambda carrageenan.